Skip to main content

Table 5 Patient demographics and oncological characteristics of patients tested positive for COVID-19

From: Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19

  2020 (n = 5)
n %
Patient demographics
Sex
 Male 5 100.00
Age
 Mean (SD)—years 60.4 (12.9)  
Socioeconomic status (IMD)
 Low 4 80.00
 Missing 1 20.00
Ethnicity
 White British 2 40.00
 Black African 1 20.00
 Other 1 20.00
 Unknown 1 20.00
Associated comorbidities
Comorbidities
 Hypertension 3 60.00
 Diabetes 3 60.00
 Lung conditions 0 0.00
 Renal impairment 1 20.00
 Liver conditions 0 0.00
 Cerebrovascular disease 0 0.00
 Frailty 1 20.00
 Long-term steroid use 0 0.00
Number of comorbidities   
 0 2 40.00
 1 0 0.00
 2 1 20.00
 3 or more 2 40.00
Medications   
 Polypharmacy 3 60.00
 NSAIDs 0 0.00
 ACE/ARB 0 0.00
 Beta-blockers 0 0.00
Oncological characteristics
Cancer type
 Prostate 2 40.00
 Renal 2 40.00
 Bladder 1 20.00
 Testicular 0 0.00
SACT   
 Chemotherapy 0 0.00
 Immunotherapy 1 20.00
 Biological/targeted 2 40.00
 Hormone 2 40.00
Treatment paradigm
 Palliative 5 100.00
COVID-19 severity
COVID-19 severity (WHO criteria)
 Asymptomatic 1 20.00
 Mild 1 20.00
 Moderate pneumonia 2 40.00
 Severe pneumonia 0 0.00
 COVID-related death 1 20.00